Intellectus Partners LLC Has $2.21 Million Stake in Celgene Co. (NASDAQ:CELG)

Intellectus Partners LLC trimmed its stake in shares of Celgene Co. (NASDAQ:CELG) by 0.7% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 22,252 shares of the biopharmaceutical company’s stock after selling 166 shares during the period. Celgene comprises about 1.0% of Intellectus Partners LLC’s portfolio, making the stock its 21st largest position. Intellectus Partners LLC’s holdings in Celgene were worth $2,210,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors also recently modified their holdings of CELG. Archford Capital Strategies LLC increased its stake in Celgene by 277.8% in the 1st quarter. Archford Capital Strategies LLC now owns 272 shares of the biopharmaceutical company’s stock valued at $26,000 after buying an additional 200 shares during the last quarter. First PREMIER Bank bought a new position in shares of Celgene in the 3rd quarter valued at about $26,000. Liberty Wealth Management LLC grew its position in shares of Celgene by 212.8% in the 2nd quarter. Liberty Wealth Management LLC now owns 294 shares of the biopharmaceutical company’s stock valued at $27,000 after acquiring an additional 200 shares during the period. Weaver Consulting Group bought a new position in shares of Celgene in the 1st quarter valued at about $29,000. Finally, Alera Investment Advisors LLC grew its position in shares of Celgene by 109.9% in the 1st quarter. Alera Investment Advisors LLC now owns 319 shares of the biopharmaceutical company’s stock valued at $30,000 after acquiring an additional 167 shares during the period. Institutional investors and hedge funds own 72.41% of the company’s stock.

In other Celgene news, insider Terrie Curran sold 11,338 shares of Celgene stock in a transaction dated Wednesday, September 18th. The shares were sold at an average price of $98.27, for a total value of $1,114,185.26. Following the completion of the sale, the insider now owns 13,493 shares in the company, valued at approximately $1,325,957.11. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 0.39% of the stock is owned by insiders.



Celgene stock traded up $0.70 during midday trading on Friday, hitting $100.51. The company’s stock had a trading volume of 673,539 shares, compared to its average volume of 3,736,602. Celgene Co. has a 1-year low of $58.59 and a 1-year high of $100.42. The company has a debt-to-equity ratio of 1.97, a current ratio of 3.44 and a quick ratio of 3.32. The company has a 50-day moving average price of $97.96 and a two-hundred day moving average price of $95.03. The company has a market cap of $70.08 billion, a price-to-earnings ratio of 13.21, a PEG ratio of 0.50 and a beta of 1.42.

Celgene (NASDAQ:CELG) last issued its quarterly earnings data on Tuesday, July 30th. The biopharmaceutical company reported $2.61 earnings per share for the quarter, topping the consensus estimate of $2.44 by $0.17. Celgene had a net margin of 32.24% and a return on equity of 89.93%. The business had revenue of $4.40 billion during the quarter, compared to analysts’ expectations of $4.22 billion. During the same quarter in the previous year, the company earned $2.16 EPS. The business’s revenue was up 15.4% on a year-over-year basis. Sell-side analysts forecast that Celgene Co. will post 9.96 EPS for the current year.

A number of research analysts have recently commented on CELG shares. BidaskClub raised shares of Celgene from a “hold” rating to a “buy” rating in a research report on Tuesday, October 1st. Mizuho downgraded shares of Celgene from a “buy” rating to a “neutral” rating and decreased their price objective for the company from $103.00 to $100.00 in a research report on Monday, August 19th. Zacks Investment Research raised shares of Celgene from a “sell” rating to a “hold” rating and set a $94.00 price objective for the company in a research report on Tuesday, July 23rd. ValuEngine downgraded shares of Celgene from a “sell” rating to a “strong sell” rating in a research report on Thursday, August 1st. Finally, Cowen reissued a “hold” rating and issued a $102.00 price objective on shares of Celgene in a research report on Tuesday, July 30th. One analyst has rated the stock with a sell rating, seventeen have given a hold rating and four have issued a buy rating to the company. The company has a consensus rating of “Hold” and an average price target of $94.60.

Celgene Company Profile

Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of cancer and inflammatory diseases worldwide. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma (MM), myelodysplastic syndromes (MDS), and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis and psoriasis; and ABRAXANE to treat breast, non-small cell lung, pancreatic, and gastric cancers.

Recommended Story: What is Compound Annual Growth Rate (CAGR)?

Institutional Ownership by Quarter for Celgene (NASDAQ:CELG)

Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.